The Indian pharma has recently seen a perceptible slide in the number of new products hitting the market. According to the analysts, slippages are more in select therapies and they attribute this to several reasons. In 2011, 3,505 pharma product brands were launched in the country, as compared to 2018, when the number dropped to 3,150. The factors contributing to this decline include: “The ban on fixed dose combination (FDC) drugs; launch of high number of “me too” brands with no real differentiation; increased regulatory scrutiny.” Some analysts also say that delay in getting new product approvals have resulted in this decline.

(Business Today)